Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Thomas P Miller, Stephen E. Jones, David S Alberts, Cindy Mackel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalInvestigational New Drugs
Volume2
Issue number1
DOIs
StatePublished - Mar 1984

Fingerprint

bisantrene
Non-Hodgkin's Lymphoma
Phlebitis
Histology
Pain

Keywords

  • bisantrene
  • non-Hodgkin's lymphomas

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. / Miller, Thomas P; Jones, Stephen E.; Alberts, David S; Mackel, Cindy.

In: Investigational New Drugs, Vol. 2, No. 1, 03.1984, p. 75-77.

Research output: Contribution to journalArticle

@article{670c0a04edc8411b9d7f124fca0992fe,
title = "Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas",
abstract = "Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40{\%} of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.",
keywords = "bisantrene, non-Hodgkin's lymphomas",
author = "Miller, {Thomas P} and Jones, {Stephen E.} and Alberts, {David S} and Cindy Mackel",
year = "1984",
month = "3",
doi = "10.1007/BF00173790",
language = "English (US)",
volume = "2",
pages = "75--77",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

AU - Miller, Thomas P

AU - Jones, Stephen E.

AU - Alberts, David S

AU - Mackel, Cindy

PY - 1984/3

Y1 - 1984/3

N2 - Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

AB - Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

KW - bisantrene

KW - non-Hodgkin's lymphomas

UR - http://www.scopus.com/inward/record.url?scp=0021280938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021280938&partnerID=8YFLogxK

U2 - 10.1007/BF00173790

DO - 10.1007/BF00173790

M3 - Article

C2 - 6469502

AN - SCOPUS:0021280938

VL - 2

SP - 75

EP - 77

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -